Comparative Pharmacology
Head-to-head clinical analysis: DTIC DOME versus LYSODREN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DTIC DOME versus LYSODREN.
DTIC-DOME vs LYSODREN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dacarbazine is an alkylating agent that forms methyltriazenoimidazole carboxamide, causing cross-linking of DNA and inhibition of DNA, RNA, and protein synthesis.
Adrenocorticolytic agent; causes adrenal cortical necrosis and suppresses adrenal steroidogenesis, especially glucocorticoids and mineralocorticoids.
DTIC 250 mg/m2 IV daily for 5 days every 21-28 days, or 850-1000 mg/m2 IV as a single dose every 21-28 days.
Oral, initial dose 2-6 g/day divided in 3-4 doses, increase gradually to 8-10 g/day. Maximum dose 18 g/day.
None Documented
None Documented
Terminal elimination half-life is approximately 5 hours (range 4-7 hours) for parent drug; metabolites exhibit longer half-life (up to 8-12 hours). Clinical context: requires multiple dosing cycles due to short half-life.
18-159 days; clinical context: during chronic therapy, steady-state may not be reached for 3-6 months.
Renal (40-60% as unchanged drug and metabolites, primarily 5-aminoimidazole-4-carboxamide); biliary/fecal (minimal, <10%)
Primarily renal excretion of metabolites; about 10% as unchanged drug. Biliary/fecal excretion accounts for <5%.
Category C
Category C
Antineoplastic
Antineoplastic